OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: GlobeNewswire
MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants of SARS-CoV-2 and also has the potential to delay resistance by emerging variants. The Phase 1 clinical trial (NCT07445971) is evaluating the safety, pharmacokinetics and tolerability of MDX2301 administered via different routes in healthy volunteers and in immune impaired adults at high risk for severe COVID-19. By combining multiple antibody binding domains in a single molecule, MDX2301 is designed to provide high potency and greater breadth compared with conventional monoclonal antibodies. This trial is being funded by the Biomedical Advanc
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- Alger Small Cap Growth Fund Q1 2026 Commentary [Seeking Alpha]Seeking Alpha
- OPKO Health (OPK) was downgraded by Barrington Research from "outperform" to "market perform".MarketBeat
- OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell LymphomasGlobeNewswire
OPK
Earnings
- 4/28/26 - In-Line
OPK
Sec Filings
- 4/28/26 - Form 10-Q
- 4/28/26 - Form 8-K
- 3/20/26 - Form 4
- OPK's page on the SEC website